Biotech M&A With a Strong Start in 2018: More Deals to Follow?
| Date | Acquirer co. | Acquirer ticker | Acquired co. | Acquired ticker | Deal value | Price/Share | CVR (if any) | Notes |
|---|---|---|---|---|---|---|---|---|
| 01/05/2018 | Takeda | TKPYY | TiGenix | G9U.BR | $626M | 1.78 euro | Belgian Co. | |
| 01/07/2018 | Celgen | CELG | Impact Biomedicines | Private | $1.1B | $7B milestones | ||
| 01/22/2018 | Sanofi | SNY | Bioverativ | BIVV | $11.6B | $105 | Belgian Co. | |
| 01/22/2018 | Celgen | CELG | Juno | JUNO | $9B | $87 | ||
| 1/29/2018 | Sanofi | SNY | Ablynx NV | ABLX | $4.8B | $55.61 | Outbid Novo Nordisk | |
| 01/29/2018 | Varian Medical Systems | VAR | Sirtex | SRX.AX | $1.28B | $28 | Australian Co. | |
| 02/13/2018 | Astellas Pharma | ALPMY | Universal Cells | Private | $102.5M | milestones to acquire 100% ownership | ||
| 02/21/2018 | Merck | MRK | Viralytics | VLA.AX | $394M | Au$1.75 | Australian Co. | |
| 04/09/2018 | Novartis | NVS | AveXis | AVXS | $8.7B | $218 | SMA GeneTherapy | |
| 04/11/2018 | Alexion | ALXN | Wilson Therapeutics | WTX.ST | $855M | $27.93 | Stockholm, Sweden, | |
| 04/26/2018 | Endo International | ENDP | Somerset Therapeutics | Private | $190M | sterile injectable and ophthalmic drugs | ||
| 04/30/2018 | United Therapeutics | UTHR | SteadyMed Ltd. | STDY | $216M | $4.46 | additional $2.63/ share upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million. | |
| 05/10/2018 | Eli Lilly | LLY | ARMO BioSciences | ARMO | $1.6B | $50 | ||
| 10/11/2018 | Gurnet Point Capital | Private Co. | Corium International | CORI | $504M | $12.5 | CVR of $0.50 per share | |
| 10/18/2018 | Novartis | NVS | Endocyte | ECYT | $2.1B | $24 | ||
| 12/03/2018 | GlaxoSmithKline | GSK | Tesaro | TSRO | $5.1B | $75 |
